Tokyo - Delayed Quote JPY

MicroAd, Inc. (9553.T)

232.00

+3.00

+(1.31%)

At close: January 31 at 3:30:00 PM GMT+9

Trump tariffs, more Big Tech earnings, and a jobs report: What to know this week

Trump's tariff plans are squarely in focus for investors amid another busy week on Wall Street that will include quarterly reports from more than 100 S&P 500 companies and the January jobs report.

Yahoo Finance 1 hour ago

^SPX

^DJI

GOOG
Vertex Pharmaceuticals Just Won a Huge FDA Approval. Is the Biotech Stock a No-Brainer Buy?

Vertex Pharmaceuticals (NASDAQ: VRTX) just snagged its second U.S. Food and Drug Administration (FDA) approval in only 41 days. On Dec. 20, 2024, the FDA gave a thumbs-up to Alyftrek in treating cystic fibrosis (CF). Last Thursday, the agency approved Vertex's Journavx in treating adults with moderate-to-severe acute pain.

Motley Fool 1 hour ago

VRTX
With Zepbound Not Matching Expectations, Should Investors Give Up on Eli Lilly?

Over the past six months, Eli Lilly (NYSE: LLY) has underperformed broader equities. While that's not much of an issue in the grand scheme of things, it is still a bit surprising, since the pharmaceutical giant is one of the undisputed leaders in the exciting market for weight loss drugs. It turns out that the anti-obesity space isn't growing as fast as Eli Lilly or analysts anticipated, resulting in lower-than-expected revenue for the company's famous weight management drug, Zepbound.

Motley Fool 1 hour ago

LLY
Why Eli Lilly and Company (LLY) Is Among the Best Long Term Low Risk Stocks to Buy Now

We recently compiled a list of the 12 Best Long Term Low Risk Stocks to Buy Right Now. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other long term low risk stocks. As the DeepSeek craze ignites a sell-off in the tech sector, investors […]

Insider Monkey 2 hours ago

LLY
This Weight Loss Stock Could Soar Over 220%, According to Wall Street. Time to Buy?

Wall Street has high hopes for development-stage pharmaceutical company Viking Therapeutics.

Motley Fool 3 hours ago

VKTX

LLY

NVO
Is Vertex Pharmaceuticals a Buy Now That the FDA Approved Its New Pain Drug?

Lately, one of America's leading pharmaceutical companies can't catch a break from Wall Street. Shares of Vertex Pharmaceuticals (NASDAQ: VRTX) are down about 9% from a peak the stock set in November, despite some highly positive news. The U.S. Food and Drug Administration (FDA) approved suzetrigine under the brand name Journavx on Jan. 30, 2025.

Motley Fool 4 hours ago

VRTX
What To Expect in the Markets This Week

Coming Up: Big Tech Earnings, the Latest Jobs Report, Consumer Sentiment Data, and More

Investopedia 4 hours ago

GOOG

LLY

NVO
Got $1,000? 2 Top Growth Stocks to Buy Right Now

If you are looking to invest in top growth stocks, these companies can experience more volatility than the average stock. Here are two top growth stocks to consider buying right now. Eli Lilly (NYSE: LLY) has been in the limelight more frequently of late, with the success of its glucagon-like peptide-1 (GLP-1) drugs that have reinvigorated growth for one of the oldest pharmaceutical companies around.

Motley Fool 5 hours ago

LLY

CHWY
How a shady hustler in Dubai turned celebrity meme coins into a crypto grift

Meme coins keep ripping off investors. Are celebrities in on the scam?

Business Insider 5 hours ago

TRX-USD

BTC-USD
Cathie Wood sells $19 million of surging tech stocks before earnings

The Nasdaq Composite gained 30% in 2024, while Ark Innovation ETF returned just 8.4%.

TheStreet 16 hours ago

RBLX

PLTR

COMP
Is Eli Lilly and Company (LLY) the Most Promising Dividend Stock According to Hedge Funds?

We recently compiled a list of the 10 Most Promising Dividend Stocks According to Hedge Funds. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other dividend stocks. During a time of great excitement about AI-driven capital gains, it’s crucial to remember that dividends have […]

Insider Monkey 18 hours ago

LLY
Vertex Pharmaceuticals price target raised to $433 from $430 at Scotiabank

Scotiabank raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $433 from $430 and keeps a Sector Perform rating on the shares. Vertex’s suzetrigine, branded Journavx, was recently approved by the FDA, which was widely expected, but the initial daily price of $31 is a bit above the threshold of $8 per day the firm’s key opinion leaders cites as the limit to ensure broad uptake, the analyst tells investors. Journavx’s value proposition as an opioid alternative, however, should not b

TipRanks yesterday

VRTX
3 Unstoppable Stocks You Can Buy and Hold for the Rest of Your Life

If you want stocks that you can buy and hold for not only years, but potentially the rest of your life, it's important to consider businesses that have massive growth opportunities. Three stocks that look unstoppable and you should be able to safely hang on to for decades are Eli Lilly (NYSE: LLY), Walmart (NYSE: WMT), and Alphabet (NASDAQ: GOOG) (NASDAQ: GOOGL). Eli Lilly has been a growth machine over the years, relying on a combination of acquisitions and in-house development to expand its operations.

Motley Fool yesterday

LLY

GOOG

WMT
Is Eli Lilly (NYSE:LLY) Using Too Much Debt?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

Simply Wall St. yesterday

LLY
Trump tariffs to hit semiconductors, oil, and more: Key details

President Trump is set to impose tariffs that will impact a variety of industries whose products are imported from China, Canada, and Mexico, including semiconductors, oil (CL=F, BZ=F), gasoline (RB=F), and other goods.  Yahoo Finance’Washington correspondent Ben Werschkul joins Asking for a Trend to further explain the details of Trump's tariff plans, which start February 1, and what Trump is prioritizing through these policies. To watch more expert insights and analysis on the latest market action, check out more Asking for a Trend here. This post was written by Josh Lynch

Yahoo Finance Video yesterday

RB=F

CL=F

BZ=F
Why Eli Lilly and Company (LLY) Is Among the Best Big Name Stocks to Invest in Now?

We recently compiled a list of the 12 Best Big Name Stocks to Invest in Now. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other best big name stocks to invest in now. Big name stocks refer to well-known companies that are widely recognized and […]

Insider Monkey yesterday

LLY

COMP

^GSPC
Chevron and Exxon close lower, tariff impacts on Big Oil

Chevron (CVX) and Exxon Mobil (XOM) both closed lower after reporting earnings results, with steep declines in refining profits due to lower fuel margins. Josh Lipton and Julie Hyman discuss the details on Market Domination Overtime in the context of President Donald Trump's plan to implement tariffs on oil (CL=F, BZ=F) and gas (RB=F) by February 18. Additionally, Trump announced plans to impose 25% tariffs on imports from Canada and Mexico and a 10% tariff on China by February 1, according to the White House. Although oil and gas tariffs could increase input costs for US oil giants, Chevron noted that the company is looking to boost production. To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime here. This post was written by Josh Lynch

Yahoo Finance Video yesterday

CVX

CL=F

XOM
Eli Lilly CEO Hasn’t Bought Company Shares in Years. He Just Bought This Stock.

Eli Lilly CEO David Ricks, also an Adobe director, paid $1 million on Jan. 28 for 2,250 shares of the software company.

Barrons.com yesterday

ADBE

LLY
These Stocks Moved the Most Today: Apple, Intel, Chevron, Exxon, Walgreens, AbbVie, Deckers, Atlassian, Vertex, and More

Apple stock rises after the tech giant posts better-than-expected earnings and guides for solid growth, Intel edges higher after revenue projections miss analysts’ estimates, and Chevron posts adjusted earnings below expectations.

Barrons.com yesterday

INTC

TEAM

DECK
How Painkillers Could Be Vertex Pharmaceuticals' Next $10 Billion Chapter

Vertex Pharmaceuticals could soon capture $10 billion in sales of non-opioid painkillers, an analyst said Friday as Vertex stock jumped.

Investor's Business Daily yesterday

VRTX

Performance Overview

Return	9553.T	Nikkei 225
YTD	+2.20%	-0.81%
1-Year	-62.28%	+9.06%
3-Year	-46.05%	+46.55%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

MicroAd, Inc. (9553.T)

Related News

Trump tariffs, more Big Tech earnings, and a jobs report: What to know this week

Vertex Pharmaceuticals Just Won a Huge FDA Approval. Is the Biotech Stock a No-Brainer Buy?

With Zepbound Not Matching Expectations, Should Investors Give Up on Eli Lilly?

Why Eli Lilly and Company (LLY) Is Among the Best Long Term Low Risk Stocks to Buy Now

This Weight Loss Stock Could Soar Over 220%, According to Wall Street. Time to Buy?

Is Vertex Pharmaceuticals a Buy Now That the FDA Approved Its New Pain Drug?

What To Expect in the Markets This Week

Got $1,000? 2 Top Growth Stocks to Buy Right Now

How a shady hustler in Dubai turned celebrity meme coins into a crypto grift

Cathie Wood sells $19 million of surging tech stocks before earnings

Is Eli Lilly and Company (LLY) the Most Promising Dividend Stock According to Hedge Funds?

Vertex Pharmaceuticals price target raised to $433 from $430 at Scotiabank

3 Unstoppable Stocks You Can Buy and Hold for the Rest of Your Life

Is Eli Lilly (NYSE:LLY) Using Too Much Debt?

Trump tariffs to hit semiconductors, oil, and more: Key details

Why Eli Lilly and Company (LLY) Is Among the Best Big Name Stocks to Invest in Now?

Chevron and Exxon close lower, tariff impacts on Big Oil

Eli Lilly CEO Hasn’t Bought Company Shares in Years. He Just Bought This Stock.

These Stocks Moved the Most Today: Apple, Intel, Chevron, Exxon, Walgreens, AbbVie, Deckers, Atlassian, Vertex, and More

How Painkillers Could Be Vertex Pharmaceuticals' Next $10 Billion Chapter

Performance Overview